IDH2 and astrocytoma (excluding glioblastoma): Based on the robust literature and the cIMPACT-NOW update 5 recommendations, astrocytoma, IDH-mutant that harbors homozygous CDKN2A/B deletion is graded as CNS WHO grade 4.